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REVIEWVaccinations against respiratory tract infections at HajjA. S. Alqahtani1,2, H. Rashid1 and A. E. Heywood3
1) National Centre for Immunisation Research and Surveillance of Vaccine Preventable Diseases, The Children’s Hospitals at Westmead, 2) School of Public
Health, The University of Sydney and 3) School of Public Health and Community Medicine, UNSW Australia, Sydney, NSW, AustraliaAbstractThe transmission of respiratory tract infections (RTIs) is very high among the Hajj congregation in Mecca, Saudi Arabia. Despite
recommendations for vaccinations, pilgrims remain at increased risk of RTIs. In this paper we systematically reviewed available studies
assessing the uptake and effectiveness of vaccinations against RTIs among Hajj pilgrims and enumerated important demographic factors, if
described, associated with vaccine uptake. Of the 42 included studies, 29 reported on the uptake and effectiveness of inﬂuenza vaccine
among pilgrims, eight studies reported the uptake of other vaccines, notably pneumococcal, diphtheria and bacillus Calmette–Guérin
vaccines, and the remaining ﬁve studies described both inﬂuenza and non-inﬂuenza vaccines. The uptake of seasonal inﬂuenza vaccine
ranged from 0.7% to 100% across the study populations, with coverage highest in the elderly and those with pre-existing co-morbidities.
The effectiveness of inﬂuenza vaccine was variable across studies but was signiﬁcantly effective against laboratory-conﬁrmed inﬂuenza
(risk ratio 0.56; 95% CI 0.41–0.75; p <0.001) in pooled metadata from six studies. Uptake of diphtheria and pneumococcal vaccines was
low, and the only study reporting pertussis among Hajj pilgrims found the presence of pre-Hajj immunity to be signiﬁcantly protective
against disease. Despite favourable evidence of effectiveness, our review shows variable uptake of vaccines across a number of studies
with few data available on the uptake of non-inﬂuenza vaccines. Mixed-method studies are needed to gauge knowledge, attitudes and
practices of Hajj pilgrims regarding vaccination, and randomized controlled trials are required to conﬁrm the efﬁcacy of vaccines and
improve uptake in this vulnerable travelling population.
Clinical Microbiology and Infection © 2014 European Society of Clinical Microbiology and Infectious Diseases. Published by Elsevier Ltd. All
rights reserved.
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E-mail: harunor.rashid@health.nsw.gov.auBackgroundEvery year, around 2–3 million people from more than 180
countries attend the Hajj pilgrimage in Mecca, Saudi Arabia, the
world’s largest annual mass gathering [1]. Another 5 million
Muslims visit Mecca and Medina (another holy city north of
Mecca) throughout the year on the minor pilgrimage, Umrah.Clinical Microbiology and Infection © 2014 European Society of CAs with other mass gatherings, Hajj attendance is associated
with an increased risk of infectious diseases. High density
crowding and large inﬂux of people during the Hajj and Umrah
pilgrimages to Mecca have been associated with numerous
outbreaks of infectious diseases, often with far reaching rami-
ﬁcations, most notably global outbreaks of cholera and
meningococcal disease [2,3]. Recently, respiratory tract in-
fections (RTIs), including inﬂuenza and tuberculosis, have been
the leading health risks at the Hajj [4,5]. Almost all pilgrims
report respiratory symptoms (e.g. cough, rhinorrhoea). RTIs
are the most common medical presentations among pilgrims
attending primary healthcare centres or hospital outpatient
clinics during the Hajj [6], and pneumonia is the leading cause of
hospital admission and a major contributing cause of intensive
care unit admissions and mortality during the Hajj [7].Clin Microbiol Infect 2015; 21: 115–127
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http://dx.doi.org/10.1016/j.cmi.2014.11.026
116 Clinical Microbiology and Infection, Volume 21 Number 2, February 2015 CMITo reduce the risk of communicable disease transmission
during the Hajj, the Ministry of Health, Saudi Arabia issues
annual recommendations including vaccination requirements
for incoming visitors [8]. Vaccination against meningococcal
serogroups A, C, W135 and Y is a strict entry visa require-
ment for all pilgrims, and poliomyelitis and yellow fever vac-
cines are compulsory for pilgrims arriving from, or transiting
through, countries where those diseases are endemic [8].
Additionally, it is recommended that pilgrims are up to date
with routine vaccinations against pertussis, diphtheria, tetanus,
polio, measles and mumps, and receive the seasonal inﬂuenza
vaccine (especially those at high-risk of severe inﬂuenza)
before travel to the Hajj [8]; pneumococcal vaccine is also
recommended by some experts [7]. Yet, the uptake and
effectiveness of vaccinations against RTIs among Hajj pilgrims
have not been reviewed systematically. The aim of this sys-
tematic review is to summarize available data on the uptake
and effectiveness of vaccines against RTIs among Hajj pilgrims
and to identify factors, if described, associated with the uptake
of vaccinations.Records identified through 
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Sc
re
en
in
g
In
cl
ud
ed
E
lig
ib
ili
ty
Id
en
tif
ic
at
io
n
Records after duplicates re
Records screened (n
Full-text articles asse
eligibility (n = 7
Studies included (n
FIG. 1. Flow diagram of systematic review searching strategy and included s
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We searched Medline from database inception to 30
September 2014 using a combination of MeSH terms and text
words including: ‘Mecca’ OR ‘Makkah’ OR ‘pilgrims’ OR
‘pilgrimage’ OR ‘Hajj’ OR ‘Hadj’, OR ‘Haj’ AND ‘respiratory
diseases/infection’ OR ‘respiratory tract diseases/infections’ OR
‘inﬂuenza virus’ OR ‘inﬂuenza’ AND ‘inﬂuenza vaccine’ OR
‘vaccines’ OR ‘vaccination’ OR ‘immunization’ OR ‘vaccine
uptake’. The same search terms were applied to other data-
bases, including CINAHL, PsycINFO, EMBASE, after ensuring
that the MeSH terms were consistent across the databases.
Google Scholar and pertinent websites including the online
Saudi Epidemiology Bulletin were also searched for relevant
studies. Finally, reference lists of included studies were hand
searched to identify additional potentially relevant papers.
Articles considered for inclusion in the review were original
studies, involving Hajj pilgrims of any age, gender and country ofAdditional records identified 
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TABLE 1. Summary of studies reporting inﬂuenza vaccine uptake and effectiveness among Hajj pilgrims
Study population Results
Departure country Study year
Individuals with co-morbidities
% (n/N)
Inﬂuenza vaccine
coverage
% (n/N) Remarks and vaccine effectiveness
Studies evaluating vaccine uptake
Saudi Arabia [13] 1998 and 2002 1 Chronic disease 13.2 (NA)
Diabetes 6.8 (NA)
Bronchial asthma 1.1 (NA)
Heart disease 2.8 (NA)
10.2 (NA) −
Saudi Arabia [15] 2002 NA 0.7 (3/451) About 9% pilgrims were advised to take inﬂuenza vaccine
whereas only a few actually received it.
Saudi Arabia [18] 2003 Smokers 11.6 (58/500) 4.4 (22/500) −
Saudi Arabia [11] 2003 Diabetes 4.6 (NA)
Bronchial asthma 1.6 (NA)
Current smokers 13.5 (NA)
10.5 (NA) −
Saudi Arabia [12] 2009 Chronic diseases 18.4 (278/1507)
Diabetes 10.3 (155/1507)
Bronchial asthma 2.1 (32/1507)
Cardiac diseases 1.4 (21/1507)
94.4 (NA) −
Multiple countries [27] 2009 Chronic diseases 13.2 (57/432)
among arriving pilgrims
Ex-smokers 15 (65/432)
53.3 (179 of 336
who provided data)
−
Multiple countries [26] 2010 27.1 (NA) 52.4 (NA) −
Multiple countries [9] 2010 NA 26.9 (NA) −
Multiple countries [47] 2013 Aged 65 years 15.4 (800/5213)
Diabetes 6.8 (11/161)
Hypertension 13.1 (21/160)
22 (1157/5235) 17.5% of vaccinated pilgrims were aged 65 years, and 36.3% (4
of 11) vaccinated pilgrims were diabetics.
Iran [48] 2004 Heart disease 2.9 (866/30037))
Diabetes 2.4 (733/30037)
Bronchial asthma and COPD
1.6 (471/30037)
74.1 (22257/30037) −
2005 Heart disease 1.4 (1075/75676)
Diabetes 2.9 (2210/75676)
Bronchial asthma and COPD
1.5 (1123/75676)
88.3 (66821/75676) −
Iran [28] 2009 NA 100 (275/275) −
Iran [35] 2009 NA 97.7 (298/305)) −
France [45] 2005 Aged >64 years 34.7 (NA) 27.3 (NA) Inﬂuenza vaccine coverage increased with age.
France [20] 2012 Chronic diseases 57.5 (NA)
Diabetes 27.5 (NA)
Respiratory disease 7.8 (NA)
Cardiac disease 7.2 (NA)
45.6 (NA) −
Australia [19] 2011 ‘At risk’ 21 (91/431) 65 (278/431) Vaccine uptake was higher in females ‘not at risk’ than males ‘not
at risk’ of inﬂuenza complications (73% versus 56%, p <0.01).
2012 ‘At risk’ 19 (100/535) 89 (476/535) Vaccine uptake was similar across the age bands.
Recommendation from tour group leaders was the main
reason given for receiving the inﬂuenza vaccine.
Australia [49] 2013 NA 83 (195/235) −
USA [17] 2009 Aged >65 years 10.8 (20/186)
Aged >65 and chronic
conditions 9.7 (18/186)
Aged <65 and chronic
conditions 7 (13/186)
63 (138/221) a −
Studies evaluating vaccine effectiveness
Multiple countries [25] 2001 Smokers 18 (55/305) 4.2 (13/305) The rate of inﬂuenza infection tended to be lower in vaccinated
pilgrims compared with unvaccinated pilgrims (7.7% versus
15.1%) but the difference was not statistically signiﬁcant (odds
ratio 0.47; 95% CI 0.01–3.33). Inﬂuenza infection was
established by serology and vaccination data were collected
through a questionnaire survey.
Multiple countries [16] 2010 Smokers 87.7 (1403/1600) 93.4 (1494/1600) There was no signiﬁcant difference in inﬂuenza infection between
vaccinated and unvaccinated pilgrims (7.4% (111/1494) versus
8.5% (9/106), p >0.05). Inﬂuenza virus was detected by PCR,
vaccination data were collected through a questionnaire
survey.
UK and Saudi Arabia [32] 2006 UK:
‘At risk’ 25 (38/150)
Aged 65 years 8 (12/150)
Diabetes 10.7 (16/150)
Lung disease 4 (6/150)
Heart disease 2 (3/150)
Kidney disease 0.7 (1/150)
37 (56/150) The rate of inﬂuenza in vaccinated and unvaccinated pilgrims was
7% and 14%, respectively (p 0.19). Inﬂuenza virus was detected
by PCR, vaccination data were collected through a
questionnaire survey.
Saudi Arabia:
‘At risk’ 14 (15/110)
Diabetes 3.6 (4/110)
Lung disease 3.6 (4/110)
Heart disease 3.6 (4/110)
4 (4/110) The rate of inﬂuenza among vaccinated and unvaccinated pilgrims
was 0% and 10% respectively (p 0.51). Inﬂuenza virus was
detected by PCR, vaccination data were collected through a
questionnaire survey.
UK [22] 2003 NA 26 (30/115) The attack rate of laboratory-conﬁrmed inﬂuenza in vaccinated
and unvaccinated pilgrims was 30% and 41%, respectively (p
0.28). Inﬂuenza infection was established by serology and
vaccination was performed by the investigators.
UK [31] 2005 28 (56/202) The proportion of inﬂuenza among vaccinated and unvaccinated
pilgrims was the same (14% (8/56) versus 14% (20/144)).
Continued
CMI Alqahtani et al. Vaccinations against respiratory tract infections at Hajj 117
Clinical Microbiology and Infection © 2014 European Society of Clinical Microbiology and Infectious Diseases. Published by Elsevier Ltd. All rights reserved, CMI, 21, 115–127
Table 1. Continued
Study population Results
Departure country Study year
Individuals with co-morbidities
% (n/N)
Inﬂuenza vaccine
coverage
% (n/N) Remarks and vaccine effectiveness
‘At risk’ group 26 (53/202)
Aged >65 years 9 (18/202)
Smokers 15 (31/202)
Inﬂuenza virus was detected by PCR, vaccination data were
collected through a questionnaire survey and subsequently
veriﬁed by primary care providers.
UK [33] 2005–2006 ‘At risk’ 21 (120/567) b
Aged 65 years 7 (40/567)
Diabetes 7.8 (44/567)
Lung disease 3.5 (20/567)
Heart disease 2.6 (15/567)
27 (148/555) b Inﬂuenza infection rate among vaccinated and unvaccinated
pilgrims was 8% (12/148) and 12% (45/390) respectively, (p
0.26). Inﬂuenza virus was detected by PCR, vaccination data
were collected through a questionnaire survey.
Iran [34] 2003 NA 10.7 (3465/32370) Inﬂuenza vaccine was associated with a reduction in ILI (56% in
vaccinated versus 71.9% in unvaccinated pilgrims with a VE of
51%, p <0.001).
ILI was deﬁned as presence of sore throat, fever over 38°C,
acute and tormenting cough with or without coryzal
symptoms and myalgia.
2004 NA 75.2 (14100/18730) Inﬂuenza vaccine was not associated with a reduction in ILI
(36.5% in vaccinated versus 33.5% in unvaccinated pilgrims
with a VE of –0.41; the difference was not statistically
signiﬁcant).
ILI was deﬁned as presence of sore throat, fever over 38°C,
acute and tormenting cough with or without coryzal
symptoms and myalgia.
Iran [21] 2006 High-risk group 33.5 (99/295) 28 (83/295) The duration of cough among vaccinated pilgrims was shorter
(8.4 days versus 13.7 days, p 0.001).
Iran [14] 2006 NA 85.5 (218/255) The rate of inﬂuenza among vaccinated versus unvaccinated
pilgrims was 9.2% versus 16.5% (p 0.19) respectively; inﬂuenza
diagnosis was established by viral culture and vaccination
history was documented.
Iran [23] 2010 Aged 60 years 45.3 (43/95) 75.8 (72/95) No association between inﬂuenza vaccine and reduction in RTIs
(crude odds ratio 1.09 (0.4–2.9), p 0.87); however, further
clinical and or biological criteria for the assessment of vaccine
effectiveness were not described, vaccination history was
anecdotal.
France [24] 2006 Chronic diseases 43 (NA)
Diabetes 22.8 (NA)
Respiratory disease 4 (NA)
34.3 (NA) Inﬂuenza vaccine was associated with a statistically non-
signiﬁcant reduction in the occurrence of afebrile cough (odds
ratio 0.67, 95% CI 0.42–1.07, p 0.07).
France [46] 2009 Age >65 years 26.3 (72/274)
Diabetes 23.7 (65/274)
Chronic respiratory
disease 5.5 (15/274)
Cardiac disease 3.3 (9/274)
Other chronic conditions
2.2 (6/274)
97.4 (267/274) Inﬂuenza vaccine was not associated with a reduction in acute
respiratory symptoms.
France [44] 2013 Chronic diseases 52.7 (68/129) 2013 (0)
(in 2012 44.2%
(57/129) received
inﬂuenza vaccine)
Compared with unvaccinated pilgrims, ILI symptoms were 34.1%
less frequent in vaccinated pilgrims in 2012 (p <0.01).
ILI was deﬁned as the presence of cough, sore throat, and
subjective fever.
Malaysia [29] 2000 Aged 60 years 31 (441/1420) 73.9 (1049/1420) Adjusted vaccine effectiveness was 77% (95% CI 69–83) against
clinic visit for ILI, and 66% (95% CI 54–75) against the receipt
of antibiotics.
ILI was deﬁned as sore throat with either cough or
documented fever 38°C.
Additionally, inﬂuenza vaccine was effective against the CDC
criteria for inﬂuenza (71%, 95% CI 53–82).
Malaysia [36] 2007 NA 72.8 (287/394) Inﬂuenza vaccination was associated with longer duration of sore
throat (p 0.03).
Pakistan [30] 1999 NA 54 (1120/2070) The ILI attack rate in vaccinated pilgrims was 36% and in
unvaccinated pilgrims 62% with a vaccine effectiveness of 38%
(95% CI 29–45).
ILI was deﬁned as sore throat with either cough or
documented fever 38°C.
Abbreviations: COPD, chronic obstructive pulmonary disease; ILI, inﬂuenza-like illness; NA, not available; VE = vaccine effectiveness.
aThe denominator is based on those who completed pre-Hajj surveys.
bThe denominators are different depending on whether those who did not undergo virological testing were included.
118 Clinical Microbiology and Infection, Volume 21 Number 2, February 2015 CMIorigin which measured the outcomes of interest, i.e. uptake
and/or effectiveness of vaccines aimed at reducing the risk of
RTIs. These included inﬂuenza, pneumococcal, pertussis, diph-
theria, bacillus Calmette–Guérin (BCG), measles, mumps and
rubella vaccines. Only English language studies were included.
Excluded studies were those that involved healthcare workers
or uniformed service personnel, reported only H1N1 pandemicClinical Microbiology and Infection © 2014 European Society of Clinical Microbiology and Infectvaccine during the 2009–10 pandemic years, the compulsory
meningococcal vaccine or vaccines against non-respiratory in-
fections, e.g. blood-borne or enteric diseases.
Two authors (ASA and AEH) independently reviewed the
titles and abstracts to identify potentially relevant papers. Full
texts of all potentially relevant papers were reviewed by both
authors to determine those which met the selection criteria.ious Diseases. Published by Elsevier Ltd. All rights reserved, CMI, 21, 115–127
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Two authors (ASA and AEH) independently extracted the data
from each study into a data extraction sheet and performed
validity assessments. The data extracted included: study design,
year of data collection, country of origin, age group, name and
type of the vaccine(s), coverage rate, uptake of other respira-
tory infection control measures including the factors affecting
the uptake, if available, and effectiveness of the vaccines. To
evaluate the data quality, the Oxford Centre for Evidence-
Based Medicine 2011 level of evidence form (http://www.
cebm.net) was used. Two authors (ASA and HR) indepen-
dently evaluated the study quality. Any disagreement was
resolved by discussion among the authors.
Statistical analysis
For the meta-analysis, the number of laboratory-conﬁrmed
inﬂuenza cases among vaccinated and unvaccinated pilgrims
was extracted from relevant studies, risk ratio (RR) of inﬂuenza
infection and p value were calculated using REVMAN 5 software
(http://tech.cochrane.org/revman), with data presented as a
forest plot.ResultsSummary of included studies
The results of the search strategy are shown in Fig. 1. Of the 70
full text articles reviewed, 42 were deemed suitable for inclusion
in this review, with these studies reporting a range of vaccines
against RTIs. Of these, 29 studies reported the uptake and/or
effectiveness of inﬂuenza vaccine alone (Table 1), another eight
studies reported the uptake of non-inﬂuenza vaccines including
pneumococcal, diphtheria, tetanus and poliomyelitis (dTP), and
BCG vaccines (Table 2), and the remaining ﬁve studies reported
the uptake of both inﬂuenza and non-inﬂuenza vaccines [9–50].
The studies were conducted between 1998 and 2013, and
involved pilgrims from a number of countries including Saudi
Arabia, Iran, UK, France, Australia, USA, Malaysia, Singapore,
Pakistan and the Netherlands. All but one study reported vac-
cine coverage among participating Hajj pilgrims, with 17 studies
also reporting the effectiveness of inﬂuenza vaccine on clinical
infection, including outcomes of inﬂuenza-like illness and
laboratory-conﬁrmed inﬂuenza and one study reporting the
effectiveness of pre-Hajj pertussis immunity.
Twenty-three studies were cross-sectional, 17 were cohort,
and the remaining two studies were case–control in design. All
cohort and cross-sectional studies were considered Level 3
evidence using the Oxford evidence-based medicine levels of
evidence, while both the case–control studies were considered
Level 4 evidence.Clinical Microbiology and Infection © 2014 European Society of Clinical MicrobiologyThe included studies described a total of 125 991 Hajj pil-
grims aged between 1 and 96 years. The gender distribution
was similar in most studies except in eight studies where the
majority of respondents were male [11,13,31,33,34,40,43,49].
The included studies are summarized in Appendix 1.
Inﬂuenza vaccine
Thirty-four studies investigated inﬂuenza vaccination (with or
without non-inﬂuenza vaccination) in Hajj pilgrims. Of these, 17
studies reported on inﬂuenza vaccine uptake
[9,11–13,15,17–20,26–28,35,45,47–49], with the remaining
17 studies additionally assessing inﬂuenza vaccine effectiveness
[10,14,16,21–25,29–34,36,44,46].
Inﬂuenza vaccine uptake. Overall, inﬂuenza vaccine uptake
ranged from 0.7% in a 2002 survey of Saudi pilgrims to 100% in
a 2009 survey of Iranian pilgrims [15,28]. The uptake of inﬂu-
enza vaccine increased over time, peaking in 2009; however,
there was a large variation across pilgrims’ country of resi-
dence. The results of these studies are summarized in Table 1.
Among the 34 studies that investigated inﬂuenza vaccine
uptake, six were conducted among Saudi Arabian pilgrims be-
tween 1998 and 2009 [11–13,15,18,32], with vaccine uptake
ranging from 0.7% in 2002 to 94.4% in 2009 [12,15]. In 1998
and 2002 Al-Maghderi et al. reported inﬂuenza vaccine uptake
of 10.2% in a sample of 1374 pilgrims [13]. In 2003 two studies
conducted in two different settings reported similarly poor
vaccine uptake: the ﬁrst was conducted at primary healthcare
centres in Riyadh reporting a vaccine coverage of 10.5% among
1027 participants [11], and the second was conducted in Mina
(Mecca) reporting a vaccine uptake of 4.4% among international
and local pilgrims [18]. In 2006, a comparative study between
the UK and Saudi Arabian pilgrims reported uptake of inﬂuenza
vaccine among Saudi pilgrims of only 4%, compared with the
uptake among UK pilgrims of 37% [32].
Six studieswere conducted in Saudi Arabia among international
pilgrims from diverse countries. In 2004, in a cross-sectional
survey of 483 international pilgrims, 29.9% pilgrims were found
to be vaccinated against inﬂuenza [10]. In a large cross-sectional
study conducted at King Abdulaziz International Airport in
2009, Memish et al. reported the uptake of inﬂuenza vaccine to be
22.9% [27]. Three additional studies were conducted in 2010with
the reported vaccination rate to be ranging from 26.9% to 93.4%
[9,16,26]. Finally, in a large 2013 survey involving 5235 interna-
tional pilgrims, Memish et al. recorded the uptake to be 22% [47].
Several studies have been conducted among pilgrims from
Iran, France, UK, Malaysia, Australia and USA, allowing a
comparison over different Hajj years. Seven studies have been
conducted among Iranian pilgrims between 2003 and 2010
showing an increase in uptake over time from 10.7% in 2003 toand Infectious Diseases. Published by Elsevier Ltd. All rights reserved, CMI, 21, 115–127
TABLE 2. Summary of studies reporting the uptake and effectiveness of non-inﬂuenza vaccines among Hajj pilgrims
Study population Study results
Departure country Study year Individuals with co-morbidities % (n/N) Vaccines studied Vaccine coverage % (n/N) Remarks
Studies evaluating vaccine uptake
France [45] 2005 Aged >64 years 34.7 (160/461) Diphtheria
Pertussis
16.1 (74/461)
10.6 (49/461)
Vaccination rate decreased with age for TDP
and pertussis.
France [38] 2006 Age 60 years 53.3 (303/569) Diphtheria NA (14.7) TdP vaccination coverage increased in the age
group 30–39 years.
French citizens were 3–4.5 times more
likely to report receiving TdP than non-
French citizens.
Low education level (lesser than the
certiﬁcate of primary studies) was
associated with a three to ﬁve times lower
TdP coverage than educated pilgrims.
France [46] 2009 Age >65 years 26.3 (72/274)
Diabetes 23.7 (65/274)
Chronic respiratory disease 5.5 (15/274)
Cardiac disease 3.3 (9/274)
Other chronic conditions 2.2 (6/274)
Pneumococcal 31.4 (86/274) Fever was less frequently reported in those
vaccinated against pneumococcal infections
(8.3% versus 14.6%, p 0.007).
France [37] 2010 >65 years without chronic disease 24.5 (155/632)
>65 with chronic disease 8 (51/632)
<65 years with chronic disease 23.1 (146/632)
Pneumococcal Overall 1.7 (11/632)
>65 years without chronic diseases 1.3 (2/
155)
>65 years with chronic diseases 2 (1/51)
<65 years with chronic diseases 3.4 (5/146)
−
France [42] 2012 Chronic diseases 57.5 (96/167) Pneumococcal
(in the past 5 years)
35.9 (47/167) Of those who had an indication for
pneumococcal vaccine according to the
French guidelines, 22 (47.8%) received the
vaccine.
France [44] 2013 1 chronic disease 52.7 (68/129) Pneumococcal
(in the last 5 years)
51.2 (66/129) −
The Netherlands [39] 2001–2009 Diabetes 19.5 (421/2156) Cardiovascular
disorders 15.9 (342/2156)
Liver/gastrointestinal disorders 11 (238/2156)
dTP (diphtheria, tetanus
and poliomyelitis)
24.4 (527/2156) Factors associated with dTP vaccine uptake:
Gender: higher uptake in females (26.9%)
Generation: higher uptake in second
generation (30%) than ﬁrst generation
(23%)
Health conditions: increasing uptake with
increasing co-morbidities
one disorder 145 (26.2%)
two disorders 67 (29.4%)
more than two disorders 29 (34.1%)
Singapore [41] 2002 Diabetes 8.8 (32/365) BCG 96.4 (346/365) −
Iran [48] 2004 NA Pneumococcal 2.5 (750/30037) −
2005 NA Pneumococcal 8.9 (6735/75676)
UK [43] 2005 ‘At risk’ 27 (53/195)Diabetes 12 (25/195)
Cardiac disease 5 (10/195)
Pulmonary disease 5 (10/195)
Pneumococcal Overall 5 (10/195)
‘At risk’ individuals 15 (8/53)
−
Australia [40] 2011 Chronic diseases 20 (32/158) Pneumococcal Overall 28.5 (45/158)
‘At risk’ individuals
30.6 (15/49)
Uptake was signiﬁcantly higher among female
than male pilgrims (p 0.03).
2012 Pre-existing disease 15.2 (78/513) Pneumococcal Overall 28.7 (147/513)
‘At risk’ individuals
45.3 (43/95)
−
2013 Pre-existing disease 12.3 (27/219) Pneumococcal Overall 14.2 (31/219)
‘At risk’ individuals 29 (9/31)
−
Multiple countries [47] 2013 Aged 65 years 15 (800/5213) Pneumococcal Overall 4.4 (232/5235)
In those 65 years 1.5 (12/800)
−
Studies evaluating vaccine effectiveness
Singapore [50] 2002 NA Pertussis vaccine NA
81.8% (293/358) had immunity against
pertussis which can be due to vaccination
or prior infection
Pre-Hajj immunity against pertussis was
signiﬁcantly associated with lower rate of
pertussis acquisition at Hajj (p 0.03).
BCG, bacillus Calmette–Guérin; dTP, diphtheria, tetanus and poliomyelitis; NA, not available; TDP or TdP, tetanus, diphtheria and poliomyelitis.
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CMI Alqahtani et al. Vaccinations against respiratory tract infections at Hajj 121100% in 2009 [14,21,23,28,34,35,48]. Five studies conducted
between 2005 and 2013 involved French pilgrims
[20,24,44–46]; three of these conducted by Gautret et al.
[24,44,46] in 2005, 2006 and 2009 also show increasing inﬂu-
enza vaccine uptake over time, of 27.3%, 34.3% and 97.4%
respectively [24,44,46]. Subsequently, the team reported a
lower uptake of 45.6% during the 2012 Hajj [20]. As the 2013
Hajj took place in mid-October none of the pilgrims in the
French cohort reported receiving the vaccine of that season;
however, 44.2% reported receiving the vaccine in the previous
northern winter season [44]. Among UK pilgrims, three studies
reported the uptake between 2003 and 2006 [22,32,33]. The
reported uptake was 26% in 2003, 27% in 2005 and 37% in
2006 [22,32,33]. The latter compared the data between British
and Saudi pilgrims with a reported uptake of 55% among ‘at
risk’ and 29% among ‘not at risk’ UK pilgrims [32]. Two studies
conducted among Malaysian pilgrims in 2002 and 2007 reported
an inﬂuenza vaccine coverage of 73.8% in 2002 and 72.8% in
2007 [29,36]. Surveys conducted among Australian pilgrims in
2011 and 2012 reporting the uptake to be 65% and 89%,
respectively [19], with a slightly lower rate of 83% in 2013 [49].
Finally, only one study has been conducted among American
pilgrims, which found that 63% had inﬂuenza vaccine [17].
Factors affecting inﬂuenza vaccine uptake. Only four studies
measured and reported on factors associated with the uptake
of inﬂuenza vaccine in pilgrims. In these studies, vaccine uptake
was higher among individuals considered ‘at risk’ of developing
severe complications from inﬂuenza infection, including pilgrims
aged over 65 years and those with pre-existing chronic diseases
[19,31,45,47]. In two Australian surveys, vaccine uptake was
higher among females not considered at risk compared with
males not considered at risk in 2011, but not in 2012 [19]. In
2012, recommendations from tour group leaders was the most
important motivating factor in the pilgrims’ decision to receive
the inﬂuenza vaccine before pilgrimage among Australian pil-
grims [19]. Summary of the results is shown in Table 1.
Inﬂuenza vaccine effectiveness. The effectiveness of the inﬂuenza
vaccine against clinical infection and laboratory-conﬁrmed
inﬂuenza were the main outcome measures of 17 included
studies (Table 2). Of these, six studies reported laboratory-
conﬁrmed inﬂuenza as an outcome [10,14,16,22,25,33], but
only one study found inﬂuenza vaccine to be effective in reducing
inﬂuenza (p <0.001) [10]. However, meta-analysis of the data
from six studies that provided both laboratory results by
vaccination status [10,14,16,22,25,33] shows that the inﬂuenza
vaccine was signiﬁcantly protective against laboratory-conﬁrmed
inﬂuenza among Hajj pilgrims (RR 0.56; 95% CI 0.41–0.75; p
<0.001) (Fig. 2). In addition, of the ﬁve studies that report on the
effectiveness of the inﬂuenza vaccine against inﬂuenza-like illness,Clinical Microbiology and Infection © 2014 European Society of Clinical Microbiologytwo studies reported a reduction in inﬂuenza-like illness in 2003
and 2012 [34,44], while the other studies conducted in 1999,
2000 and 2004 did not ﬁnd any reduction [29,30,34]. One study
also reported a signiﬁcant reduction in clinic visits and antibiotic
use for inﬂuenza-like illness in vaccine recipients [29]. Vaccine
effectiveness against self-reported respiratory symptoms was
reported in three studies [23,36,46]. None of these found a
signiﬁcant association between inﬂuenza vaccination and a
reduction in respiratory symptoms [23,36,46]. Finally, the
effectiveness of inﬂuenza vaccination against cough was reported
in two studies, whereas one study found that the vaccine was
associated with shorter duration of cough [21], the other study
did not ﬁnd any association [24].
Uptake of other recommended vaccines
Thirteen studies reported the uptake of other vaccines
including pneumococcal polysaccharide vaccine (n = 8), dTP
(n = 3), pertussis (n = 1) and BCG (n = 1) (Table 2) [37–48,50];
of these, four studies also measured and reported factors
associated with the uptake of these vaccines [38–40,45], and
one study assessed the effectiveness of pertussis vaccine [50].
Pneumococcal vaccine. Eight studies reported the uptake of
pneumococcal vaccination [37,40,42–44,46–48]. Pneumo-
coccal vaccine uptake was ﬁrst reported among Iranian pilgrims
at the 2004 and 2005 Hajj pilgrimages with 2.5% and 8.9% pil-
grims vaccinated respectively [48]. Subsequently, 5% of UK
pilgrims attending the 2005 Hajj reported pneumococcal
vaccination with uptake among ‘at risk’ pilgrims of 15% [43].
Among French pilgrims, reported vaccine uptake across the
four studies was variable, at 31.4% in 2009, 1.7% (3.4% in in-
dividuals under 65 years with co-morbidities) in 2010, 35.9%
(47.8% in those with co-morbidities) in 2012 and 51.2% in 2013
[37,42,44,46]. In a series of surveys involving Australian pil-
grims, the rates of vaccine uptake in 2011, 2012 and 2013 were
28.5% (in ‘at risk’ 30.6%), 28.7% (in ‘at risk’ 45.3%) and 14.2%
(in ‘at risk’ 29%), respectively [40]. In a study conducted among
international pilgrims in 2013, 4.4% of pilgrims reported they
were up to date with their pneumococcal vaccination [47].
dTP and BCG vaccines. Analysis of a large database of pre-travel
clinic visits by Hajj pilgrims from the Netherlands between
2001 and 2009 identiﬁed that only 24% of those recommended
dTP vaccine actually accepted it [39]. Three studies in 2005, 2006
and 2009 among French pilgrims found low rates of self-reported
diphtheria and pertussis vaccination [38,45,46], and lower rates
on validation against vaccination records [38]. In 2005, self-
reported rates of vaccination against diphtheria and pertussis
were 16.1% and 10.6%, respectively, while a much lower pro-
portion (8.9% and 2.4%, respectively) had certiﬁed proof of
vaccination [45]. In 2006, only 14.7% pilgrims gave a history ofand Infectious Diseases. Published by Elsevier Ltd. All rights reserved, CMI, 21, 115–127
FIG. 2. Forest plot of included studies reporting laboratory-conﬁrmed inﬂuenza infection by vaccination status.
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vaccination certiﬁcates, for dTP was 4.5% [38]. Only one study
reported the uptake of BCG vaccine: in a study conducted among
pilgrims from Singapore in 2003 the rate of BCG vaccination was
96.4% according to vaccination history or presence of BCG scar
[41]. Summary of the results is shown in Table 2.
Factors affecting the uptake of non-inﬂuenza vaccines. Four studies
reported factors associated with the uptake of vaccines other
than inﬂuenza (Table 2) [38–40,45]. Age, gender and the pres-
ence of risk factors were associated with higher vaccine uptake in
two studies [38,39]. In two studies, conducted among French
pilgrims in 2005 and 2006, dTP vaccine coverage was higher in
women and younger individuals [38,45]. Among Australian pil-
grims in 2011, pneumococcal vaccine uptake was higher in males
than females [40]. The results are summarized in Table 2.
Effectiveness of other vaccines. Of the 13 studies measuring the
uptake of vaccines other than inﬂuenza, only one study assessed
vaccine effectiveness. Wilder-Smith et al. demonstrated that
pilgrims with no documented evidence of pre-Hajj immunity,
deﬁned as the absence of antibodies against pertussis, had
signiﬁcantly higher risk of pertussis acquisition at the Hajj
compared with those who had evidence of pre-Hajj immunity
(odds ratio 6.7; 95% CI 1.1–42.2) [50].DiscussionThis systematic review of observational studies of Hajj pilgrims
demonstrates the high variability in the reported uptake of
vaccinations against respiratory infections in this population.
Although inﬂuenza vaccine coverage appears to be increasing in
both low-risk and high-risk pilgrims, the limited available studies
show that the uptake of other vaccines is sub-optimally low.
Moreover, there are no data on the uptake or effectiveness of
other vaccines such as measles/mumps/rubella used in travel
clinics in this population. Encouragingly, the pooled data from
the available studies show inﬂuenza vaccine to be protective
against laboratory-conﬁrmed inﬂuenza in this population, andClinical Microbiology and Infection © 2014 European Society of Clinical Microbiology and Infectdata from a single study show that the incidence of pertussis is
lower in pilgrims with evidence of prior immunity [50].
Among vaccines against respiratory infections, inﬂuenza vac-
cine is the most studied in Hajj pilgrims. The uptake of inﬂuenza
vaccine is improving year on year from a level of 0.7% in 2002 to
100% in 2009 [15,28], and then showing slight decline but still
maintaining an acceptable coverage of around 75% in some study
countries, including Australia and Iran [19,23,49]. Not surpris-
ingly, the highest record of vaccination was observed in 2009, the
pandemic year. This could be partly a result of heightened global
awareness at the time of the pandemic and the stringent pre-
ventive measures recommended by the Saudi Arabian authority
at the time [51]. There are other examples of pandemic threat
increasing population uptake of the seasonal inﬂuenza vaccine
[52]. But the effect of the pandemic on improving uptake of
seasonal inﬂuenza vaccine among travellers has not been studied,
and the vaccine coverage among non-Hajj travellers remains
generally low and under-used. For instance, in an Australian
survey in 2010, only 25% of student travellers reported ‘ever’
receiving inﬂuenza vaccine [53]; similarly, in a small survey con-
ducted among UK travellers, reported inﬂuenza vaccination for
the preceding 5 years was only 21% [54].
Among all surveyed pilgrims, the Saudi Arabian pilgrims had
the lowest inﬂuenza vaccine coverage (excluding the pandemic
year when one study reported uptake of 94%), although a
comparative study has shown that the risk of inﬂuenza among
Saudi pilgrims is similar to that of international pilgrims [32].
This low coverage could result from misperceptions sur-
rounding inﬂuenza vaccine. Lack of awareness and access to
vaccination were the two most important factors in inﬂuenza
vaccine refusal among pilgrims in a large study involving a
considerable proportion of Saudi Arabian pilgrims [27]. Mis-
perceptions are also reported among Australian Hajj pilgrims;
for example, respectively 33% and 26% of the Australian pil-
grims who reported not receiving inﬂuenza vaccine in 2011 and
2012 claimed to have relied on ‘natural immunity’ [19]. Mis-
perceptions surrounding inﬂuenza have been reported even
from Saudi healthcare workers deployed at the Hajj [55].
However, variability in the uptake of inﬂuenza in the includedious Diseases. Published by Elsevier Ltd. All rights reserved, CMI, 21, 115–127
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to recall bias or the timing of the survey, commencing before
the national vaccination campaign, as happened in the study
conducted by Benkouiten et al. who found that none of the
French pilgrims received inﬂuenza vaccine in 2013 [44].
Only a handful of studies explored the factors affecting the
uptake of inﬂuenza vaccine among pilgrims. Age, gender and
pre-existing health conditions were important factors in higher
reported uptake of inﬂuenza vaccination among Hajj pilgrims.
This reﬂects both national recommendations for inﬂuenza
vaccination and the Saudi Arabian Ministry of Health policy,
which strongly encourages inﬂuenza vaccination for the elderly,
those with chronic medical conditions and pregnant women
attending Hajj [8]. Interestingly, in some studies women were
found to have higher inﬂuenza or dTP vaccination rates but
lower pneumococcal vaccination coverage [19,39,40]; those
could be chance ﬁndings as the phenomenon was not consistent
across the studies.
Metadata from included observational studies found inﬂu-
enza vaccine to be effective against laboratory-conﬁrmed
inﬂuenza. Although ﬁve of the six included studies did not
individually show a statistically signiﬁcant protective effect of
the vaccine [10,14,16,22,25,33], this is probably reﬂective of
small sample sizes, as already acknowledged in one study [33].
All studies demonstrated non-signiﬁcant point estimates of
protection by the vaccine, and the pooled data conﬁrm that the
vaccine is effective, corresponding with evidence from other
settings [56]. However, it remains unproven whether the
prevalence of inﬂuenza at Hajj is declining over time as the
vaccine uptake is increasing year on year. Moreover, as the
laboratory tests used in these studies vary, a deﬁnitive
conclusion should be not drawn from this analysis.
Despite Saudi Ministry of Health recommendations, there are
limited studies examining the uptake and effectiveness of respi-
ratory vaccines other than inﬂuenza, such as diphtheria, pertussis
and pneumococcal vaccines, and the coverage of reported vac-
cines was generally very low. This is unsurprising in view of the
fact that vaccine uptake is generally low both among adult
travellers and non-travellers even in developed countries
[57,58]. Studies of knowledge, attitudes and practices of Hajj
pilgrims regarding pre-travel vaccinations are required to gain
better understanding of why the coverage is low and how it can
be improved. All Hajj studies conducted so far are quantitative,
and reported only uptake and effectiveness; however, qualitative
studies are also needed to explore the pilgrims’ experience,
beliefs about vaccinations, and to better understand the barriers
and facilitators of other infection control measures. Our team is
currently conducting a large mixed methods study to ﬁll those
knowledge gaps and have commenced a large multinational test-Clinical Microbiology and Infection © 2014 European Society of Clinical Microbiologynegative case–control study to provide further evidence of the
effectiveness of inﬂuenza vaccine in this setting.
To our knowledge, this is the ﬁrst paper that has system-
atically reviewed the uptake and effectiveness of vaccinations
against respiratory infections and provided meta-data on the
effectiveness of inﬂuenza vaccine against laboratory-conﬁrmed
inﬂuenza in Hajj pilgrims. This review has some limitations,
stemming from the quality of the included papers. Owing to the
limited number of relevant studies, we have used an ‘inclusive’
search strategy, thus data synthesized in this study were derived
from studies of moderate to poor quality, and in most instances
vaccination data were not validated, instead relying on self-
reported vaccination history, the validity of which may be
questionable. In other settings, the validity of self-reported
vaccination was found to be low, especially for pneumococcal
vaccine [59], but at least one study has shown that the sensi-
tivity and speciﬁcity of self-reported inﬂuenza in the past year
was sufﬁciently high [60]. A few Hajj studies, however, provided
separate data for self-reported and documented vaccination
records and conﬁrmed that a difference exists [38,45].
Furthermore, the heterogeneity in deﬁning inﬂuenza-like illness
and RTI precluded us from determining the effectiveness of
inﬂuenza vaccination against broader clinical outcomes, and
non-English language articles were excluded. Despite these
limitations, this review provides a useful summary of available
data on vaccine coverage and effectiveness of recommended
vaccines against respiratory infections among Hajj pilgrims, and
revealed important research gaps in the ﬁeld.
In conclusion, the uptake of vaccines against respiratory in-
fections in Hajj pilgrims is still sub-optimal, and improvements
are needed as part of a comprehensive infection control
strategy to reduce the incidence of vaccine-preventable respi-
ratory infections during the Hajj.Contributions of authorsASA and AEH searched, screened, identiﬁed and reviewed the
relevant papers, and abstracted the data. HR performed data
synthesis and meta-analysis. All authors contributed to the
writing of the manuscript.Transparency declarationHR received fees from Pﬁzer or Novartis for consulting or
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for investigator-driven research from GSK and Sanoﬁ Pasteur.
ASA has no competing interests to declare.and Infectious Diseases. Published by Elsevier Ltd. All rights reserved, CMI, 21, 115–127
124 Clinical Microbiology and Infection, Volume 21 Number 2, February 2015 CMIAppendix 1. Summary of the study
characteristicsStudy design Study participants
Source country Hajj year
Data collection
method Recruitment site
Final sample
(response rate %) Male (%)
Mean age in years
(range)
Cohort studies
France, Marseille [24] 2006 Pre/post survey Travel medicine
centre, Hôpital
Nord, Marseille
580 (89.2) 330 (56.9) 58
(20–85)
France, Marseille [46] 2009 Pre/post survey Travel medicine
centre, Hôpital
Nord, Marseille
274 (67.7) 144 (52.4) 58
(23–83)
France [20] 2012 Pre/post survey
Nasal swabs
Private specialized
travel agency in the
city of Marseille
165 (81.5) 64 (38.3) 59.3
(21–83)
France [42] 2012 Pre/post survey
Nasal swabs
Pilgrims departing
from Marseille,
France
169 (98.8) NA NA
France [44] 2013 Pre/post survey
Paired nasal
and throat
swab specimens
At a private specialized
travel agency in
Marseille
129 (100) 52 (40.3) 61.7 (34–85)
UK [22] 2003 Pre/post survey
Blood sample
East London Mosque 115 (NA) NA NA
UK [33] 2005–2006 Pre/post survey
Nasal swabs
Multiple settings
UK: Hotel/tent
clinics in Mecca
KSA: National
Guard Health Affairs
Clinics in Mecca
538 (94.9) 498 (90) Median 41
(1–85)
UK and Saudi
Arabia [32]
2006 Pre/post survey
Nasal swabs
Multiple settings
British: hotel/tent
clinics, Mecca
Saudi: National
Guard Health Affairs
clinics, Clinics in
Mina Mecca
British: 150 (100)
Saudi: 110 (100)
British: 139 (92)
Saudi: 109 (99)
British: Median 41 (14–81)
Saudi: Median 30
(16–85)
Iran [34] 2003–2004 Pre/post survey Recruitment unclear,
selected from
caravans during Hajj,
Mecca
2003: 32 370 (NA)
2004: 18 730 (NA)
NA NA
Iran [48] 2004–2005 During Hajj study Pre-travel clinical and
Para-clinical
assessment followed
up by a survey
during Hajj in Mecca
2004: 30 037 (NA)
2005: 75 676 (NA)
2004: 16 413 (54.7)
2005: 38 595 (51)
2004: 53.5 (NA)
2005: 52.5 (NA)
Iran [21] 2006 Pre/during Hajj survey Iranian pilgrims
travelling by caravan
in Saudi Arabia
295 (NA) 168 (56.9) 52.1
(20–85)
Singapore [41] 2002 Pre/post survey
Blood sample
Mandatory
meningococcal
vaccine sites
357 (74) 139 (38) 49.2
(18–75)
Singapore [50] 2002 Pre/post survey
Blood sample
Muslim Centre in
Singapore
358 (73) 129 (36) 48
(16–75)
USA [17] 2009 Pre/post survey Minnesota: Hajj clinic
Michigan: multiple
settings—mosques,
health clinics,
airport
186 (84.2) 92 (49.5) 48.9
(16–89)
Pakistan [30] 1999 Pre/post survey Vaccine ‘sessions’,
hotels, clinics,
Mecca
2070
(83.8)
1077 (52) 45
(14–86)
Saudi Arabia [11] 2003 Pre/post survey Primary healthcare
centres, Riyadh
1027 (NA) NA (73) 33.5 (SD ± 11.7)
Saudi Arabia [12] 2009 Pre/post Hajj survey During meningococcal
vaccination session
at primary
healthcare centres,
Riyadh
1507 (83.5) (61.7) 37.9 (12–83)
Cross sectional studies
Multiple countries [13] 1998
2002
Survey during Hajj Mina (Mecca) 1374 (NA) NA (86.4) 43 (NA)
Multiple countries [18] 2003 Survey during Hajj Attendees with upper
respiratory tract
infection, National
Guard Health Affairs
Clinics in Mina
(Mecca)
500 (NA) 264 (52.8) NA (their age ranged
from 0 to 50+; 55.4%
were aged
20–39 years)
Saudi Arabia [16] 2010 Survey during Hajj
Pharyngeal swabs
King Abdulaziz
International
1600 (NA) 997 (62.3) NA (40 years 291
(18.2%) >40 years
1309 (81.8%))
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Study design Study participants
Source country Hajj year
Data collection
method Recruitment site
Final sample
(response rate %) Male (%)
Mean age in years
(range)
Airport, Jeddah city,
KSA
Multiple countries [25] 2001 Survey during Hajj
and serosurvey
Three major hospitals
in Mecca
305 (NA) 274 (89.8) NA (15 to +60)
Multiple countries [15] 2003 Survey during Hajj Mina (Mecca) 451 (NA) NA (69.4) NA
Multiple countries [10] 2005 Survey during Hajj
Nasal swabs
Various sites 483 (NA) NA 51.6 (13–96)
Multiple countries [27] 2009 2 cross-sectional studies
pre/post Hajj
Nasopharyngeal and
throat swab samples
King Abdulaziz
International
Airport, Jeddah
Pre-Hajj: 432 (55.2)
Post-Hajj:2768
Pre-Hajj: 282 of
374 (75.4)
Post-Hajj: 1414
of 2528 (55.9)
Pre-Hajj: 44.7 (SD ± 13.9)
Post-Hajj: 50 (SD ± 13.4)
Multiple countries [26] 2010 Post-Hajj survey Hajj terminal of King
Abdulaziz
International
Airport, Jeddah
1717 (NA) NA (63.7) 46.2 (±SD 11.53)
Multiple countries [9] 2010 Survey during Hajj
Throat swabs
King Abdulaziz
International
Airport, Jeddah
713 (NA) NA (68.2) 48.9 (SD ± 12.2)
Multiple countries [47] 2013 Post-Hajj survey
Nasopharyngeal
samples
Hajj terminal of King
Abdulaziz
International
Airport, Jeddah
5235 (NA) 2831 (54) 51.8
(18–93)
France [45] 2005 Pre-Hajj survey Travel medicine
centre, Hôpital
Nord, Marseille
461 (NA) 270 (58.6) Median 61
(20–84)
France [37] 2010 Pre-Hajj survey Marseille travel
medicine centres
632 (NA) 343 (54.3) Median 62 (19–87)
UK [31] 2005 Survey during Hajj
Nasal swabs
Attendees of ‘British
Hajj Delegation
Clinic’ in Mecca
202
(98.5)
182 (90) 44 (1.5–83)
UK [43] 2005 Survey during the Hajj Attendees of ‘British
Hajj Delegation
Clinic’ in Mecca
195 (NA) NA (91) NA (1–83)
Iran [14] 2006 Post-Hajj Nasal wash Shiraz airport, Iran,
post-Hajj
255
(NA)
120 (47.1) 52.4
(19–82)
Iran [28] 2009 Post-Hajj survey
Throat swabs
Shiraz airport, Iran,
post-Hajj
275 (NA) NA (50.9) Median 46
(20–70)
Iran [35] 2009 Post-Hajj survey
Pharyngeal swabs
Shiraz airport, Iran,
post-Hajj
305 (NA) 132 (43.3) 49.2 (SD ± 8.8)
Australia [40] 2011, 2012 and 2013 Survey during Hajj Mina (Mecca) In 2011:158(NA)
In 2012: 531(NA)
In 2013: 219 (NA)
2011: 67 (42.4)
2012: 325 (63.4)
2013: 127 (78.5)
2011: 43.8 (SD ± 13)
2012: 43 (SD ± 13.5)
2013: 42.6 (SD ± 12.3)
Australia [19] 2011 and 2012 Survey during Hajj Mina (Mecca) In 2011: 431(98)
In 2012: 535 (97)
2011:
235 (55)
2012: 334 (62)
2011: Median 42 (7–86)
2012: Median 43 (12–83)
Australia [49] 2013 Survey during Hajj Mina (Mecca) 229 (NA) 178 (77.9) 42.4 (SD ± 12.7)
Malaysia [36] 2007 Survey during Hajj Malaysian transit
centre in Mecca
387 (98.2) 219 (56.6) 50.4 (SD ± 11)
The Netherlands [39] 2001–2009 Clinic database Public health service
pre-travel clinic
8372 (NA) 4672 (55.8) NA (49.2% were aged
40–59 years)
Case–control studies
Malaysia [29] 2002 Survey during Hajj Hotel clinics in Mecca 820 Cases (NA)
600 Controls (NA)
Cases:
367 of 792 (46.3)
Controls:
198 of 597 (33)
Cases: NA (71% were
aged <60 years)
Controls: NA (65%
were aged
<60 years)
Iran [23] 2010 Survey during Hajj Iranian pilgrims who
attended the Hajj
2010
32 Cases (NA)
63 Controls (NA)
Cases: 20 (62.5)
Controls: 35 (55.6)
Cases: NA (43.8% were
aged <60 years)
Controls: NA (60.3%
were aged
<60 years)
Abbreviations: NA, not available; SD, standard deviation.
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